Supplemental Figure 2. Patient disposition. AE=adverse event; Q2W=every 2 weeks; SC=subcutaneous. *One subject had multiple major protocol violations and discontinued from the study: (1) actual treatment was not according to randomization assignment; (2) premature unblinding; (3) use of an opioid/non-steroidal anti-inflammatory drug for >50% of the days before week 16; (4) baseline patient assessment of hand pain intensity in both hands (11-point numeric rating scale) <4; (5) absence (<2 joints) of tenderness and/or swelling on examination of the distal and proximal interphalangeal joints during screening; and (6) absence of erosive or erosive with remodeling phase joint on hand radiograph defined by Verbruggen-Veys et al.[2] †One subject had bronchitis at the time of randomization to lutikizumab, was not administered study drug, and subsequently discontinued from the study.